Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Paul Choi from Goldman Sachs remains neutral on the stock and has a $70.00 price target.
Paul Choi of Goldman Sachs has given his Buy rating due to a combination of factors that underscore the potential of Arvinas Holding Company. Choi highlights the company’s innovative protein degrader platform, which sets it apart in the market for breast cancer treatments and other areas. This technological edge, particularly with the drug vepdegestrant (ARV-471), is seen as a significant driver for market expansion. The recent data presented at SABCS 2023 strengthens the case for the company’s growth prospects in the short to medium term, with a particularly keen eye on the commercial opportunities in the second-line treatment setting and beyond for breast cancer.
Moreover, Choi sees Arvinas as an attractive strategic target for potential acquirers due to its advanced oncology assets and the robust clinical profile of its leading candidate. The company’s potential in various therapeutic areas, such as prostate cancer, hematology, and neurology, further bolsters its strategic value. The risk/reward profile is deemed attractive, considering both near-term catalysts and longer-term commercial opportunities. This assessment supports the initiation of a Buy rating with a 12-month price target of $70, suggesting confidence in Arvinas’ largely de-risked late-stage assets and its upside potential from market expansion opportunities.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arvinas Holding Company (ARVN) Company Description:
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Read More on ARVN:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Capital One says buy these six biotech stocks for 2024
- Capital One reveals top six biotech picks for 2024
- Arvinas Appoints Jared Freedberg as General Counsel
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Outperform in 2024
